Existing anti-virals and new drugs in the pipeline, traditional viral suppressive therapies, strategies and industrial resources available to reduce the price of production and distribution -- these factors come together here with clinical trials and academic research to speed anti-viral solutions.
This content is created by the open source Your Priorities citizen engagement platform designed by the non profit Citizens Foundation